AU5748300A - Il-8 receptor antagonists - Google Patents

Il-8 receptor antagonists

Info

Publication number
AU5748300A
AU5748300A AU57483/00A AU5748300A AU5748300A AU 5748300 A AU5748300 A AU 5748300A AU 57483/00 A AU57483/00 A AU 57483/00A AU 5748300 A AU5748300 A AU 5748300A AU 5748300 A AU5748300 A AU 5748300A
Authority
AU
Australia
Prior art keywords
receptor antagonists
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU57483/00A
Inventor
Gregory M. Benson
Deborah L. Bryan
John G. Gleason
Katherine L. Widdowson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU5748300A publication Critical patent/AU5748300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU57483/00A 1999-06-16 2000-06-16 Il-8 receptor antagonists Abandoned AU5748300A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13967799P 1999-06-16 1999-06-16
US60139677 1999-06-16
PCT/US2000/016814 WO2000076517A1 (en) 1999-06-16 2000-06-16 Il-8 receptor antagonists

Publications (1)

Publication Number Publication Date
AU5748300A true AU5748300A (en) 2001-01-02

Family

ID=22487800

Family Applications (1)

Application Number Title Priority Date Filing Date
AU57483/00A Abandoned AU5748300A (en) 1999-06-16 2000-06-16 Il-8 receptor antagonists

Country Status (9)

Country Link
EP (1) EP1185270A4 (en)
JP (1) JP2003501472A (en)
AU (1) AU5748300A (en)
CO (1) CO5190712A1 (en)
EC (1) ECSP003527A (en)
HK (1) HK1044475A1 (en)
PE (1) PE20010321A1 (en)
UY (1) UY26207A1 (en)
WO (1) WO2000076517A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642215B2 (en) * 2001-05-24 2003-11-04 Leo Pharma A/S Method of modulating NF-kB activity
WO2005113534A2 (en) 2004-05-12 2005-12-01 Schering Corporation Cxcr1 and cxcr2 chemokine antagonists
CN108463218A (en) * 2015-09-30 2018-08-28 药物分子研究所 Weaken the method for parasite virulence

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2928485A1 (en) * 1979-07-14 1981-01-29 Bayer Ag USE OF UREA DERIVATIVES AS A MEDICINAL PRODUCT IN THE TREATMENT OF FATTY METABOLISM DISORDERS
JPH0678298B2 (en) * 1988-03-30 1994-10-05 ワーナー‐ランバート・コンパニー N-[[(2,6-disubstituted) phenyl] -N'-arylalkyl] ureas
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
WO1998006399A1 (en) * 1996-08-15 1998-02-19 Smithkline Beecham Corporation Il-8 receptor antagonists

Also Published As

Publication number Publication date
EP1185270A4 (en) 2004-02-11
ECSP003527A (en) 2002-01-25
UY26207A1 (en) 2000-12-29
PE20010321A1 (en) 2001-05-18
EP1185270A1 (en) 2002-03-13
WO2000076517A1 (en) 2000-12-21
HK1044475A1 (en) 2002-10-25
JP2003501472A (en) 2003-01-14
CO5190712A1 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
PL352232A1 (en) Il-8 receptor antagonists
AU2001245724A1 (en) Il-8 receptor antagonists
AU2001240021A1 (en) Diazafluorenone il-8 receptor antagonists
IL145762A0 (en) Il-8 receptor antagonists
AU2001243351A1 (en) Il-8 receptor antagonists
PL351946A1 (en) Il-8 receptor antagonists
AU6435098A (en) Il-8 receptor antagonists
AU2001253172A1 (en) Il-8 receptor antagonists
AU2001241896A1 (en) Il-8 receptor antagonists
HUP0201302A3 (en) Il-8 receptor antagonists
AU2234199A (en) Il-8 receptor antagonists
AU6051200A (en) Il-8 receptor antagonists
AU2001245605A1 (en) Il-8 receptor antagonists
AU2574801A (en) Selective iGLUR5 receptor antagonists
AU5748300A (en) Il-8 receptor antagonists
AU5168900A (en) Il-8 receptor antagonists
AU5622400A (en) Il-8 receptor antagonists
AU1588501A (en) Il-8 receptor antagonists
HUP0202004A3 (en) Il-8 receptor antagonists
HUP0202019A3 (en) Il-8 receptor antagonists
AU2328999A (en) Il-8 receptor antagonists
AU2512800A (en) Alpha1-adrenergic receptor antagonists

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase